{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-040919","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.734617+00:00","generated_at":"2026-06-19T09:42:39.739344+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vor Bio announces additional Phase 1/2a data: trem-cel protects against Mylotarg hematotoxicity in AML patients","bullets":["First AML patient maintained neutrophil and platelet counts ~5 months post trem-cel transplant through three Mylotarg doses at 0.5 mg/m².","No Mylotarg-related hematotoxicity observed; only low-grade nausea/vomiting reported as possibly related.","Second patient engrafted normally with neutrophil recovery Day 11, platelet recovery Day 17; no unexpected AEs in both patients.","CD33-negative donor hematopoiesis enriched across cell types after Mylotarg, suggesting potential for combo therapy.","Company on track to file IND in H1 2023 for VCAR33 ALLO allogeneic CAR-T to combine with trem-cel."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-040919","json":"https://secwatch.observer/filing/0001193125-23-040919.json","markdown":"https://secwatch.observer/filing/0001193125-23-040919.md","text":"https://secwatch.observer/filing/0001193125-23-040919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523040919/0001193125-23-040919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523040919/d449789d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:42:39.739344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}